louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02699775: Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients
Official title: Effect of 3 Consecutives Botulinum Toxin Injection on Gait Pattern in Stroke Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Botulinum Toxins Injection in Stroke Patients
Keywords: Botulinum toxin injections
Stroke
3D motion analysis
Gait pattern
Lead sponsor: Centre d'Investigation Clinique et Technologique 805
Sponsor class: OTHER
Collaborators: name: Fondation Garches
First posted: 2016-03-04
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: STROKE PATIENTS

Brief summary: Chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(BTI). Several studies demonstrated that single BTI-session in a single muscle of paretic lower limb(LL) improved kinematic gait parameters(GP) but surprisingly none of them assessed the effects of repetitive multifocal BTI on patient's gait pattern and their duration.

The aim was to evaluate the impact of repetitive multifocal BTI-sessions on GP of chronic stroke patients. To that end, gait of patients will be compared using 3D-gait analysis after 3 consecutives BTI sessions.

Detailed description: All the patients will be treated with BTI . These injections will be performed under electrical stimulation control (\~5mA). The dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. The dilution the most commonly used will be 100 U for 2.5ml (XEOMIN®)

Eligibility criteria: Inclusion Criteria:

* \>18 years
* a single hemispheric cerebral vascular lesion more than 6 months previously
* able to walk 10 meters without any assistance
* having benefited of at least 2 consecutive BTI sessions, second 3D gait analysis performed at least 3 months after the last BTI.

Exclusion Criteria:

* patient's refusal to participate to the study
* Inability to read the selected text
* Inability to cooperate
* No affiliation to social security

Primary outcomes:
measure: kinematics gait parameters
timeFrame: 3h
Secondary outcomes:
measure: spatiotemporal gait parameters
timeFrame: 3h
Other outcomes:
Locations:
city: Garches
country: France
facility: Raymond Poincaré hospital
Study officials:
affiliation: Raymond Poincare Hospital
name: Nicolas ROCHE, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01285375: Safety and Preliminary Efficacy of the Treatment of Kidney Allografts With Curcumin-containing Preservation Solution
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: End Stage Renal Failure With Renal Transplant
Lead sponsor: Helsinki University Central Hospital
Sponsor class: OTHER
Collaborators: name: University of Helsinki
name: Academy of Finland
First posted: 2011-01-28
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The safety and preliminary efficacy of the addition of an aqueous curcumin-cyclodextrin complex (CDC) solution to graft perfusion solution is studied. CDC has proved safe and highly effective in preventing primary graft non-function, delayed graft function and chronic dysfunction in pre-clinical kidney transplantation animal models. The hypothesis is that addition of CDC to the graft perfusion solution will decrease the incidence of delayed graft function in human kidney transplantation subjects.


Eligibility criteria: Inclusion Criteria:

* Patients with ESRD assigned for kidney transplantation, written informed consent

Exclusion Criteria:

* None

Primary outcomes:
measure: Delayed Graft Function
timeFrame: 7 days
Secondary outcomes:
measure: Primary non-function
timeFrame: 1 year
measure: Acute rejection
timeFrame: 1 year
measure: Graft function eGFR
timeFrame: 30 days, 90 days
measure: Graft Survival
timeFrame: 1 year
measure: Patient Survival
timeFrame: 1 year
measure: Length of stay in hospital
timeFrame: upto 1 year
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: Helsinki University Central Hospital
Study officials:
affiliation: Head of Kidney Transplantation Unit
name: Kaija Salmela, Docent
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03270475: Effect of Exercise on Muscle Proteome Signature
Official title: Effect of Exercise Training on Skeletal Muscle Proteome Signature of Young Men
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2017-09-01
Enrollment: 8
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to investigate skeletal muscle proteome signature changes induced by exercise training in young men

Detailed description: Advances in omics technologies have allowed for the identification of biomarkers with importance for the beneficial adaptations imposed by exercise training. Skeletal muscle exhibits remarkable plasticity to exercise training, as illustrated by pronounced alterations to the proteomic landscape, such as mitochondrial biogenesis. However, despite recent advances that have helped describe the proteomic landscape in response to a period of exercise training, our understanding of the processes pertaining to post-translation modification is scant. In this study, we aim to investigate the human acetylome and proteome in response to exercise training.

Eligibility criteria: Inclusion Criteria:

* Healthy
* VO2max of 45-55 ml/kg/min (+/- SD) / 3000-4000 ml/min (+/- SD)
* Body mass index (BMI) of 19-26 kg/m2
* Normal ECG (electrocardiography)

Exclusion Criteria:

* Serious adverse effects to exercise
* Chronic disease

Primary outcomes:
measure: Skeletal muscle proteome signature
timeFrame: Change from baseline proteome signature at 5 weeks
Secondary outcomes:
Other outcomes:
measure: Skeletal muscle acetylome signature
timeFrame: Change from baseline acetylome signature at 5 weeks
measure: Skeletal muscle mitochondrial respiration
timeFrame: Change from baseline at 5 weeks
measure: Maximal oxygen uptake
timeFrame: Change from baseline at 5 weeks
Locations:
city: Copenhagen
country: Denmark
facility: Department of Nutrition, Exercise and Sports
Study officials:
References:
Clinical trial NCT02636075: "Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"
Official title: "Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Parathyroid Hyperplasia
Lead sponsor: SB Istanbul Education and Research Hospital
Sponsor class: OTHER
First posted: 2015-12-21
Enrollment: 125
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: no limitaion

Brief summary: This study investigates if Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases or not.

Detailed description: Parathyroid tissues gets heavier when they become Hyperplasia. Because of this weight change, they change their normal anatomic positions. 125 patients who have been operated earlier will be included in the study.

Eligibility criteria: Inclusion Criteria:

* Patients who have undergone an operation due to parathyroid hyperplasia

Exclusion Criteria:

-

Primary outcomes:
measure: Size of the thyroid tissue
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Vakıf Gureba University
name: Erhan Aysan, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00004375: Ultraviolet Light Therapy for Systemic Lupus Erythematosus
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Systemic Lupus Erythematosus
Keywords: arthritis & connective tissue diseases
immunologic disorders and infectious disorders
rare disease
systemic lupus erythematosus
Lead sponsor: National Center for Research Resources (NCRR)
Sponsor class: NIH
Collaborators: name: Louisiana State University Health Sciences Center in New Orleans
First posted: 1999-10-19
Enrollment: 20
Sex: ALL
Minimum age (years): 15
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Primary purpose: TREATMENT

Brief summary: OBJECTIVES:

I. Evaluate the mechanisms of ultraviolet A-1 light therapy in patients with systemic lupus erythematosus and normal controls.

Detailed description: PROTOCOL OUTLINE:

Treatment with ultraviolet A-1 light is administered 5 days a week for 6 weeks, at the lowest dose or frequency required to maintain a response. The dose and frequency are progressively decreased over the next 9 weeks.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Patients ages 15 to 70 with symptomatic systemic lupus erythematosus meeting American Rheumatism Association criteria and normal controls

--Prior/Concurrent Therapy--

No requirement for tetracycline or other photosensitizing drugs

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Orleans
country: United States
facility: General Clinical Research Center and Charity Hospital (University of Louisiana)
state: Louisiana
city: New Orleans
country: United States
facility: Alton Ochsner Medical Foundation Hospital
state: Louisiana
Study officials:
affiliation: Louisiana State University Health Sciences Center in New Orleans
name: Hugh McGrath, Jr.
role: STUDY_CHAIR
References:
citation: McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340-400 nm) irradiation therapy in systemic lupus erythematosus. Lupus. 1996 Aug;5(4):269-74. doi: 10.1177/096120339600500405.
Clinical trial NCT05299775: Poor Quality of Life Associated With Traditional Chinese Medicine Constitution in HIV-infected Men Who Have Sex With Men
Official title: Poor Quality of Life Associated With Traditional Chinese Medicine Constitution in HIV-infected Men Who Have Sex With Men
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HIV Infections
Quality of Life
Lead sponsor: Taipei City Hospital
Sponsor class: OTHER_GOV
First posted: 2022-03-29
Enrollment: 203
Sex: MALE
Minimum age (years): 20
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: We invited all people diagnosed with HIV infected through MSM in the outpatient Department of Infection, Taipei City United Hospital, Linsen Chinese Medicine and Kunming Branch, to participate in this study.

Brief summary: This study explores the pathological constitution as it relates to low quality of life with HIV- infected MSM patients, as a reference for clinical treatment.

Detailed description: Introduction :This study explores the pathological constitution as it relates to low quality of life with HIV- infected MSM patients, as a reference for clinical treatment.

Methods :It has a cross-sectional research design using structured questionnaires to collect data,including patient's basic case data, CD4+, CD4+/CD8+ ratio, Wang Qi constitution and WHOQOL-BREF -Taiwan version questionnaires. We consider the association between the constitutions and quality of life for HIV-infected MSM patients.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with HIV infected.
* Age greater than 20 years old (including) and less than 60 years old.
* Conscious clear and voluntary to attend the project with agreement.
* Willing to fill out the informed consent form.

Exclusion Criteria:

* conscious unclear
* Patients had histories of severe psychiatric disorders ( ex: schizophrenia) or if they met the criteria of Diagnostic and Statistical Manual of Mental Disorders ( ex: dementia)
* Age \< 20 years old.
* The patient does not want to fill out the informed consent form for any reason.

Primary outcomes:
measure: quality of life score
timeFrame: Lasts for 1 year
measure: TCM constitution
timeFrame: Lasts for 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei City Hospital
Study officials:
affiliation: clinical professor
name: Chung-Hua Hsu
role: STUDY_DIRECTOR
References:
Clinical trial NCT01845675: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Official title: Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
Keywords: temozolomide
endostatin
advanced
well-differentiated
pancreatic neuroendocrine tumor
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2013-05-03
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Temozolomide or dacarbazine-based chemotherapy combined with endostatin have efficacy in well-differentiated pancreatic neuroendocrine tumor


Eligibility criteria: Inclusion Criteria:

1. 18 years of age and older
2. ECOG ≤2
3. Pathologically confirmed locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumor.
4. Prior treatment with one-line chemotherapy is allowed, with the exception of prior treatment with temozolomide or dacarbazine or endostatin within the past 6 months
5. Disease progressed during or after last therapy
6. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of all prior systemic anticancer therapy
7. Disease progressed within the past 12 months。
8. Patients must have at least one measurable site of disease according to RECIST1.1 criteria that has not been previously irradiated.
9. Adequate bone marrow, liver and renal function
10. Life expectancy 3 months or more
11. Patient informed consent。

Exclusion Criteria:

1. Concurrent use of Octreotide or other drug that may have efficacy in neuroendocrine tumor.
2. 2 or more lines of prior chemotherapy。
3. Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
4. Uncontrolled infectious disease。
5. Other malignancies within the past 5 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinoma of the skin
6. Uncontrolled brain or leptomeningeal metastases
7. Patients with known hypersensitivity to temozolomide or endostatin。
8. Patient could not take tablets。

Primary outcomes:
measure: overall response rate
timeFrame: up to 12 months
Secondary outcomes:
measure: progression free survival
timeFrame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
measure: toxicities
timeFrame: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Other outcomes:
Locations:
city: Beijing
country: China
facility: Division of Medical Oncology, Peking Union Medical College Hospital
Study officials:
References:
Clinical trial NCT01135875: Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
Official title: Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glioblastoma Multiforme
Healthy Volunteers
Keywords: GBM
Brain Tumor
Brain Neoplasm
Control
Normal Control
Volunteer
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2010-06-03
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants will be recruited during routine interactions with the investigators.

Brief summary: The purpose of this study is to determine if tumor cells can be detected in the blood of patients diagnosed with a brain tumor.

Detailed description: Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are increasingly recognized for occasionally metastasizing through the peripheral blood to distant locations. This research study involves the detection and novel characterization of human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor patients by identifying their unique cell surface antigen profile, determining an optimal isolation protocol, and quantitatively and qualitatively reporting the yield and characteristics.

Eligibility criteria: Inclusion Criteria:

* 18 to 89 years of age
* Weight of at least 110 pounds
* Able to provide informed consent for self

Exclusion Criteria:

* Patients with active malignant tumors other than GBM

Primary outcomes:
measure: Identification of Human GBM CD Antigen Signature.
timeFrame: 3 Years
Secondary outcomes:
measure: Identification & Isolation of Human GBM Cells in Seeded Normal Control Human Blood.
timeFrame: 3 Years
measure: Prospective Isolation of GBM Tumor Cells in GBM Patient Blood.
timeFrame: 3 Years
measure: Prospective Evaluation of the Routine Medical History of GBM Patients.
timeFrame: 3 Years
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Brent Reynolds, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06753175: Underwater Galvanic Stimulation by 4-Cell Bath on Lymphedema.
Official title: Underwater Galvanic Stimulation by 4-Cell Bath on Lymphedema Post Mastectomy.
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Lymphedema
Keywords: Mastectomy
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-12-31
Enrollment: 60
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Sixty female patients with lymphedema post mastectomy, aged 30-55 years, will be selected from Minia Oncology Institute. The participants will be randomly distributed into two equal groups:

1. Group A (CDT + Underwater Galvanic Stimulation group):

   This group includes 30 patients who will receive underwater galvanic stimulation by 4-cell bath with CDT for 2 months (3times/week) in addition to their medical treatment.
2. Group B (CDT group):

This group includes 30 patients who will receive only CDT for 2 months (3times/week) in addition to their medical treatment.


Eligibility criteria: Inclusion Criteria:

* ▪ Female patients with lymphedema post mastectomy

  * Aged 30-55 years
  * No history of cardiac or renal disease
  * No contraindications to electrotherapy
  * All patients enrolled to the study will have their informed consent.

Exclusion Criteria:

* ▪ Cardiac diseases.

  * Patients with active cancer
  * Patients with pacemakers or other implantable devices
  * Patients with a history of seizures or epilepsy

Primary outcomes:
measure: Measuring pain intensity:
timeFrame: 2 months
measure: Measuring the volume of a patient's upper limb:
timeFrame: 2 months
measure: Improvement in quality of life:
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06879275: Incidence of Body Dysmorphic Disorder (BDD) in a Population of Patients Undergoing Orthognathic Surgery
Official title: Incidence of Body Dysmorphic Disorder (BDD) in a Population of Patients Undergoing Orthognathic Surgery: a Prospective Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Orthognathic Surgical Procedures
Psychiatric Disorders
Prognathism
Keywords: orthognatic surgery
body dismorphic disorder
prognathism
aesthetic surgery
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2025-03-17
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: candidates to orthognathic surgery

Brief summary: Assessment of the incidence of Body dismorphic disorder in a population candidated to orthognathic surgery

Detailed description: Assessment of the incidence of Body dismorphic disorder in a population candidated to orthognathic surgery by using 3 validated questionnaires

Eligibility criteria: Inclusion Criteria:

* Patients who are candidates for orthognathic surgery
* Age: 18 to 50 years;
* Informed consent

Exclusion Criteria:

* - Patients diagnosed with another psychiatric pathology
* Patients affected by syndromes involving the cervical-facial district
* Patients affected by clefts
* Patients affected by OSAS and candidates for orthognathic surgery for this indication
* Patients affected by connective tissue disorders (e.g. Ehler-Danlos, scleroderma, etc.)
* Patients candidates for orthognathic surgery due to facial trauma

Primary outcomes:
measure: primary outcomes
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Fondazione Policlinico Gemelli IRCSS
state: RM
Study officials:
affiliation: Fondazione Policlinico Universitario A. Gemelli, IRCCS
name: Alessandro Moro, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01744275: HOPE-Epilepsy Trial
Official title: High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
PHASE3
Conditions: Epilepsy
Keywords: Epilepsy
Omega 3 fatty acids
Lead sponsor: Hospital do Coracao
Sponsor class: OTHER
First posted: 2012-12-06
Enrollment: 370
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This a multi-center study to examine whether supplementation with omega 3 fatty acids will reduce seizure frequency in patients with epilepsy .


Eligibility criteria: Inclusion Criteria:

* Patients with active Epilepsy

Exclusion Criteria:

* pregnant women or breastfeeding

Primary outcomes:
measure: Seizure Frequency
timeFrame: 18 months
Secondary outcomes:
measure: categorized seizure frequency
timeFrame: 18 months
measure: Percentage of overall seizure frequency modification
timeFrame: 18 months
measure: Time Free of seizures during treatment
timeFrame: 12 months
measure: Reduction in seizure frequency
timeFrame: 12 months
measure: Quality of Life
timeFrame: 12 months
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Research Institute, Hospital do Coração
Study officials:
affiliation: Hospital do Coracao
name: M J Carrion, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital do Coracao
name: O Berwanger, PhD
role: STUDY_CHAIR
affiliation: BCRI
name: R D Lopes, PhD
role: STUDY_CHAIR
affiliation: Federal University of São Paulo
name: F A Scorza, PhD
role: STUDY_CHAIR
References: